Transaction covers Xoma’s bacterial cell-expression technology and Wacker’s E. coli secretion platform.
Wacker Biotech has received nonexclusive worldwide rights to use Xoma’s bacterial cell-expression technology for R&D purposes. As a result, Wacker says they will now be able to combine the company’s E. coli secretion technology with Xoma’s platform to produce antibodies and antibody fragments.
In return, Xoma will receive access to Wacker’s E. coli secretion technology for one of its development projects.
